Form 4: Fennec Pharmaceuticals CFO Robert Andrade Reports Share Acquisition
SEC Form 4 Filing
Robert Andrade, CFO of Fennec Pharmaceuticals, reports the acquisition of 1,042 common shares on August 31, 2024.
Summary
- Robert Andrade, the Chief Financial Officer of Fennec Pharmaceuticals, reported a transaction on August 31, 2024.
- Andrade acquired 1,042 common shares of Fennec Pharmaceuticals.
- The acquisition price was $0 per share.
- Following the transaction, Andrade beneficially owns 109,481 common shares.
- The shares were released from restriction from shares awarded 3-31-2023.
Sentiment
Score: 5
Explanation: Neutral sentiment as it's a standard regulatory filing. The acquisition of shares by the CFO could be seen as a positive signal, but without further context, it's difficult to assess the overall impact.
Positives
- The acquisition increases Andrade's stake in the company, potentially signaling confidence in its future prospects.
Industry Context
Form 4 filings are standard practice and provide transparency into the transactions of company insiders, allowing investors to track management's alignment with shareholder interests.
Key Dates
| Date | Description |
|---|---|
| 03/31/2023 | Date of original share award. |
| 08/31/2024 | Date of the reported transaction (share acquisition). |
| 09/04/2024 | Date of signature on the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.